PPARG and Insulin resistance: Pioglitazone which belongs to thiazolidinedione (TZDs) is a peroxisome proliferator-activated receptor (PPAR)-γ agonist that reduces insulin resistance by stimulating lipogenesis, suppressing lipolysis in the adipose tissue and decreasing hepatic triglycerides, visceral fat mass, and activity, thus promoting peripheral insulin sensitivity [28].